These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20585396)

  • 1. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.
    Yewdall AW; Drutman SB; Jinwala F; Bahjat KS; Bhardwaj N
    PLoS One; 2010 Jun; 5(6):e11144. PubMed ID: 20585396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines.
    Petersen TR; Sika-Paotonu D; Knight DA; Simkins HM; Hermans IF
    PLoS One; 2011 Mar; 6(3):e17657. PubMed ID: 21483862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
    Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
    Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.
    Liang X; Fu C; Cui W; Ober-Blöbaum JL; Zahner SP; Shrikant PA; Clausen BE; Flavell RA; Mellman I; Jiang A
    J Leukoc Biol; 2014 Jan; 95(1):179-90. PubMed ID: 24023259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
    Paglia P; Chiodoni C; Rodolfo M; Colombo MP
    J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
    Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
    Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
    Kim JH; Kang TH; Noh KH; Bae HC; Kim SH; Yoo YD; Seong SY; Kim TW
    Immunol Lett; 2009 Jan; 122(1):58-67. PubMed ID: 19135479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DC-Based Vaccines for Cancer Immunotherapy.
    Fu C; Zhou L; Mi QS; Jiang A
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33255895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
    van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
    Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide-pulsed splenic dendritic cells prime long-lasting CD8(+) T cell memory in the absence of cross-priming by host APC.
    Livingstone AM; Kuhn M
    Eur J Immunol; 2002 Jan; 32(1):281-90. PubMed ID: 11782019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
    Fu C; Jiang A
    Front Immunol; 2018; 9():3059. PubMed ID: 30619378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses.
    Huang MN; Nicholson LT; Batich KA; Swartz AM; Kopin D; Wellford S; Prabhakar VK; Woroniecka K; Nair SK; Fecci PE; Sampson JH; Gunn MD
    J Clin Invest; 2020 Feb; 130(2):774-788. PubMed ID: 31661470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
    Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
    Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis.
    Oh S; Perera LP; Terabe M; Ni L; Waldmann TA; Berzofsky JA
    Proc Natl Acad Sci U S A; 2008 Apr; 105(13):5201-6. PubMed ID: 18362335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.
    Kretz-Rommel A; Qin F; Dakappagari N; Torensma R; Faas S; Wu D; Bowdish KS
    J Immunother; 2007 Oct; 30(7):715-26. PubMed ID: 17893564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo.
    Kleindienst P; Brocker T
    J Immunol; 2003 Mar; 170(6):2817-23. PubMed ID: 12626531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.